Atlas Trials

Systemic Vascular Endothelial Growth Factor (VEGF) Protein Dynamics Following Intravitreal Injections of Ranibizumab Versus Aflibercept in Patients With Neovascular Age-related Macular Degeneration

Clinical trial NCT02257632 · COMPLETED

Trial details

NCT number
NCT02257632
Sponsor
Novartis Pharmaceuticals
Status
COMPLETED
Phase
Phase 4
Study type
INTERVENTIONAL
Wet Age-Related Macular Degeneration
Start date
2015-04-08
Primary completion
2017-03-20
Enrollment
41

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.